Arterez – Scientific Breakthrough Predict, Prevent and Cure Cardiovascular Disease

Join Our Exclusive Family Office Investor Event to learn more about Arterez.

Cardiovascular Disease (CVD) is the world’s leading chronic killer impacting more than one-third of the world’s population. US direct and indirect healthcare costs due to CVD is expected to grow to an estimated $1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the largest health risk and cost.

Dr. J.B. Tunac and Arterez believe they have discovered the multi-factorial root causes of chronic vascular disease and that those can be identified, characterized, cured and ultimately prevented. The company’s first drug, Embotricin™, targets healing at the cellular level rather than targeting symptoms. The company has also developed a biomarker panel for treatment monitoring, known as GlycoCardia™ that can also be used for disease identification, staging and classification. Embotricin™ proved to prevent and reverse arterial plaques in models and proved non-toxic up to 300x the effective dose. First in-human studies are expected to begin Q1 2023.